Publications

CANCERS 2026

Transarterial Chemoembolization Versus Transarterial Radioembolization in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trial Evidence

Transarterial chemoembolization and transarterial radioembolization are both established locoregional options for hepatocellular carcinoma, yet direct comparative evidence is complicated by variation in disease stage, patient selection, procedural technique,…

CHEST 2025

Depression, Anxiety and Sleep Disorders Among Patients with Interstitial Lung Disease in the United States: A Systematic Literature Review

Depression, anxiety, and sleep disorders can add substantially to the burden of interstitial lung disease, but prevalence estimates in the United States have been difficult to interpret because…

EUROPEAN HEMATOLOGY ASSOCIATION 2026

A Systematic Assessment of Diffuse Large B-Cell Lymphoma Cell-of-Origin Classification Performance Evaluating Non-Inferiority of the Hans Immunohistochemistry Algorithm to Gene Expression Profiling

Cell-of-origin classification is an established component of diffuse large B-cell lymphoma characterization, but the optimal testing approach remains debated. Gene expression profiling is often treated as the reference…

INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2026 – PHILADELPHIA

Inflation Reduction Act Negotiations: Qualitative Insights from 25 Medicare Part D Drug Price Negotiations

Publicly reported negotiated prices under the Medicare Drug Price Negotiation Program provide drug-level information, but viewing each product in isolation makes it difficult to see broader patterns across…

INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2026 – PHILADELPHIA

Real-World Diagnostic Delay, Treatment Access, and Health System Burden in Primary Immunodeficiency/Inborn Errors of Immunity: Evidence from the United States and ex-US Settings

For primary immunodeficiency and inborn errors of immunity, recurrent infections are only one part of the burden. Delayed recognition, repeated healthcare use before diagnosis, access to genetic testing…

INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2026 – PHILADELPHIA

Unit-Consistent Translation of Treatment Effects into Number Needed to Treat and Cost per Event Avoided in Health Economic Evaluations

Number needed to treat is frequently used to translate treatment effects into an intuitive decision metric, but the calculation is only meaningful when it matches the structure of…

INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2026 – PHILADELPHIA

Implementation of Managed-Entry Agreements in HTA Submissions: Types, Use-Cases, and Operational Considerations

Managed-entry agreements are used when a promising health technology reaches reimbursement decision-making with unresolved financial, clinical, or implementation uncertainty. Across jurisdictions, however, these arrangements are described and implemented…

INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2026 – PHILADELPHIA

Confidence Intervals for Event-Based Number Needed to Treat: A Practical Approach for Health Economic Evaluation Outputs

Number needed to treat is intuitive when the outcome is binary. It expresses how many patients must be treated to prevent one additional event. Recurrent outcomes such as…

INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2025 – GLASGOW

Evaluating the Performance of a Supervised Artificial Intelligence Model in Screening Abstracts for Oncology-Focused Targeted Literature Reviews

Artificial intelligence can reduce the manual burden of literature screening, but evidence reviews in oncology pose a difficult test. Eligibility criteria often combine disease sub-types, line of therapy,…

HEOR, INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2025 – GLASGOW

Measures for Integrating Carbon Footprints into Economic Evaluations: A Targeted Review of Environmental and Economic Metrics

Healthcare decisions increasingly need to account for environmental consequences as well as clinical outcomes and costs. Yet carbon emissions do not fit automatically into conventional cost-effectiveness or budget…

Indence Publications

Transarterial Chemoembolization Versus Transarterial Radioembolization in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trial Evidence

Depression, Anxiety and Sleep Disorders Among Patients with Interstitial Lung Disease in the United States: A Systematic Literature Review

A Systematic Assessment of Diffuse Large B-Cell Lymphoma Cell-of-Origin Classification Performance Evaluating Non-Inferiority of the Hans Immunohistochemistry Algorithm to Gene Expression Profiling

Inflation Reduction Act Negotiations: Qualitative Insights from 25 Medicare Part D Drug Price Negotiations

Real-World Diagnostic Delay, Treatment Access, and Health System Burden in Primary Immunodeficiency/Inborn Errors of Immunity: Evidence from the United States and ex-US Settings

Unit-Consistent Translation of Treatment Effects into Number Needed to Treat and Cost per Event Avoided in Health Economic Evaluations

Implementation of Managed-Entry Agreements in HTA Submissions: Types, Use-Cases, and Operational Considerations

Confidence Intervals for Event-Based Number Needed to Treat: A Practical Approach for Health Economic Evaluation Outputs

Evaluating the Performance of a Supervised Artificial Intelligence Model in Screening Abstracts for Oncology-Focused Targeted Literature Reviews

Measures for Integrating Carbon Footprints into Economic Evaluations: A Targeted Review of Environmental and Economic Metrics

Services

Legal

Quick Links